Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Validation of Coregistered CT-PET Imaging in Determining Tumor Volume and Atelectasis in Patients With Operable Non-Small-Cell Lung Cancer and Tumor Associated Atelectasis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2008 by Radboud University.
Recruitment status was  Recruiting
Information provided by:
Radboud University Identifier:
First received: September 12, 2005
Last updated: June 3, 2008
Last verified: June 2008

CT-PET image fusion has the potential to differentiate 'tumor' from 'atelectasis' much better than the CT-scan in patients with non-small cell lung cancer who also have atelectasis.

This however has never been validated on a histological level. In this study patients with non small cell lung cancer and atelectasis who are eligible for surgery undergo a CT-scan and a PET-scan prior to surgery.

The resection specimen will be compared to the preoperative imaging.

Condition Intervention
Carcinoma, Non Small Cell Lung
Procedure: CT-scan, PET-scan

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: The Validation of Coregistered CT-PET Imaging in Determining Tumor Volume and Atelectasis in Patients With Operable Non-Small-Cell Lung Cancer and Tumor Associated Atelectasis With Histological Examination of the Resected Specimen

Resource links provided by NLM:

Further study details as provided by Radboud University:

Primary Outcome Measures:
  • Histological validation of CT-PET image fusion.

Estimated Enrollment: 15
Study Start Date: June 2004

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

-Patients with non small cell lung cancer and atelectasis, who are eligible for surgery.

Exclusion Criteria:

  • age < 18 years
  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00184964

Contact: Dominic A Schinagl, MD +31243614515

Radboud University Nijmegen Medical Centre Recruiting
Nijmegen, Gelderland, Netherlands, 6500HB
Contact: Dominic A Schinagl, MD    +31243614515   
Principal Investigator: Dominic A Schinagl, MD         
Sponsors and Collaborators
Radboud University
Study Director: Jan Bussink, MD, PhD Radiation oncologist, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  More Information

No publications provided Identifier: NCT00184964     History of Changes
Other Study ID Numbers: 2004/032
Study First Received: September 12, 2005
Last Updated: June 3, 2008
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Lung Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms processed this record on March 03, 2015